PCV9 CARDIOVASCULAR EVENT REDUCTION AFTER TREATMENT WITH SIMVASTATIN PLUS NIACIN EXTENDED-RELEASE COMBINATION THERAPY VERSUS GENERIC SIMVASTATIN THERAPY FROM A MANAGED CARE ORGANIZATIONS PERSPECTIVE IN THE UNITED STATES
Abstract
Authors
S Balu RA Quimbo RJ Simko MJ Cziraky